At Home Nursing Care Brings Top-Tier In-Home Caregivers to San Diego, CA
San Diego, CA - At Home Nursing, a leading provider of home care services, today reaffirmed its ongoing mission to supply the most qualified and compassionate in-home caregivers in the San Diego area. Under the guidance of Lauren Reynolds, the agency continues to set the standard for excellence, ensuring that families have a trusted partner for the well-being of their loved ones. This sustained focus addresses the growing need for dependable and professional care that allows individuals to thrive in the comfort and familiarity of their own homes.
As the population ages and more families seek alternatives to institutional care, the demand for high-quality home care has never been greater. Navigating this landscape can be overwhelming, with families often facing the challenge of finding caregivers who are not only skilled but also genuinely compassionate and reliable. At Home Nursing directly confronts this challenge by dedicating its resources to recruiting, training, and retaining the very best care professionals, thereby providing a solution that families can count on.
One of the primary benefits of partnering with At Home Nursing is the delivery of highly personalized care plans. The agency recognizes that every individual has unique needs and preferences. Therefore, they work closely with clients and their families to develop a customized regimen of care, whether it involves assistance with daily activities, medication management, or more specialized support. This tailored approach ensures that each client receives the precise level of care required to maintain their independence and enhance their quality of life.
Furthermore, the agency provides an unparalleled level of trust and security. Families seeking an in-home caregiver in San Diego can rest assured knowing that every professional from At Home Nursing has undergone a rigorous vetting process, including comprehensive background checks, credential verification, and in-depth interviews. This commitment to hiring only the most qualified individuals means that clients are cared for by professionals who are not only skilled but also dedicated to providing respectful, dignified, and empathetic support.
"Our goal has always been more than just providing a service; it's about becoming a trusted extension of the family," says Lauren Reynolds, founder of At Home Nursing Care. "We understand the immense trust placed in us when we are invited into a home. That's why we are unwavering in our mission to supply the most compassionate and skilled caregivers, ensuring every client receives the dignified and respectful care they deserve."
As At Home Nursing moves forward, its core mission remains the essential driver of its operations. By focusing on the quality of its caregivers and the specific needs of each client, the agency solidifies its reputation as the premier source for home care in San Diego, CA. Families in need of dedicated and professional care are encouraged to contact the agency to learn more about its comprehensive services.
For more information about At Home Nursing Care and their in-home caregivers in San Diego, CA, please visit their website at https://athomenursingcare.com
About At Home Nursing Care:
Founded on the belief that everyone deserves dignified, high-quality care at home, At Home Nursing has become a trusted name in home care in San Diego, CA. The company rigorously screens and trains its caregivers, emphasizing empathy, reliability, and skill. Services range from personal care and meal preparation to specialized medical support, all designed to enhance clients' quality of life.
Media Contact
Company Name: At Home Nursing Care
Contact Person: Lauren Reynolds
Email: Send Email
Phone: +1 760 634 8000
Address: 531 Encinitas Blvd #120
City: Encinitas
State: CA
Country: United States
Website: https://athomenursingcare.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
Pulmatrix (PULM) Q2 Revenue Falls 100%
Key Points GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a substantial reduction in R&D activity. Pulmatrix focused on finalizing its merger with Cullgen and pursuing asset divestitures; no forward financial guidance was provided. These 10 stocks could mint the next wave of millionaires › Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025. Net loss per share (GAAP) was $(0.42), compared to $(1.59) in Q2 2024. There were no Wall Street analyst estimates available this quarter, but the reported GAAP loss per share of $(0.42) represented a substantial narrowing from last year's GAAP result of $(1.59) in Q2 2024, mainly due to a near-total reduction in research and development spending. The quarter highlights Pulmatrix's strategic pivot: winding down its prior clinical business, trimming operational costs, conserving cash, and focusing on completing its merger with Cullgen. The company offered no forward guidance for upcoming quarters as it transitions operations. Business Overview and Recent Areas of Focus Pulmatrix's core business has centered on developing inhaled therapies using its proprietary iSPERSE™ technology—a dry powder drug delivery platform aimed at improving medication delivery to the lungs. This platform was designed to increase efficiency and tolerability in treatments compared to traditional inhalers or oral medications, positioning the company in the respiratory therapeutics space. Over the past year, Pulmatrix's strategic priorities have shifted dramatically. It has halted most clinical operations, halted R&D spending, and now seeks to divest its iSPERSE™ intellectual property and remaining clinical assets. The company's ongoing viability depends on successfully completing its pending merger with Cullgen and monetizing its assets or securing royalty streams from former drug candidates such as PUR1900. Key success factors now rest less on product development and more on the execution of these strategic transactions. Quarter Highlights: Operations, Finances, and Pipeline Progress The quarter reflected a sharp operational downsizing as Pulmatrix's GAAP revenue dropped from $1.6 million in Q2 2024 to zero. This change resulted from the completion of the wind-down of its PUR1900 clinical trial. Former sources of operating income, such as milestone payments or funding for joint studies, concluded, and there were no new business or sales streams to replace them during the period. Research and development expense (GAAP) decreased from $2,834,000 in Q2 2024 to $14,000, a 99.5% drop. This near-total reduction in research spending came as Pulmatrix finished closing its flagship clinical programs and terminated related staff. The company stated: 'The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.' Helped by layoffs and cuts, although these savings were partially offset by legal and advisory expenses linked to the merger process. Net loss and operating loss (GAAP) both narrowed substantially. The reduced losses were primarily due to a sharp decrease in R&D expenses. Net loss (GAAP) dropped to $(1.55) million from $(5.81) million in Q2 2024. The company avoided any unusual charges this quarter, whereas the prior period had included a significant loss from an asset transaction with MannKind. With its extreme cost containment, Pulmatrix exited the quarter with a GAAP cash and cash equivalents position of $5.8 million (down from $9.5 million at December 31, 2024), which management expects will fund operations until the Cullgen merger is finalized. This period also saw Pulmatrix focus on two main strategic moves apart from operational cuts: the attempted sale of its iSPERSE™ intellectual property and clinical programs, and its merger with Cullgen. The company openly stated, 'Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.' These pipeline programs include PUR3100 for acute migraine (an orally inhaled dihydroergotamine engineered with iSPERSE™), PUR1800 for chronic obstructive pulmonary disease (a kinase inhibitor also using the iSPERSE™ platform), and PUR1900 (an inhaled formulation of an antifungal, developed with Cipla). Development or commercial responsibility for these candidates has ended or shifted to partners, and Pulmatrix itself has no ongoing clinical trials. Regulatory milestones from past years continued to carry some legacy value. For example, the Food and Drug Administration had accepted a Phase 2 study for PUR3100 and Pulmatrix's partner Cipla is moving forward with Phase 3 for PUR1900 in India. Pulmatrix may be eligible to receive a 2% royalty on possible future non-U.S. sales of PUR1900, but this would only occur if the product is successfully commercialized—a long-term and uncertain proposition. The most critical development during the second quarter was continued progress toward completing the merger with Cullgen, a protein degrader drug development company. Pulmatrix received stockholder approval and had its registration statement declared effective by the Securities and Exchange Commission. The merger remains contingent on regulatory approvals, including from the China Security Regulatory Commission and Nasdaq. Until the deal closes, Pulmatrix is in a holding pattern, and the company highlights that any delay or failure in closing poses significant risks to its ongoing viability. Looking Ahead: Guidance and Watchpoints Pulmatrix did not provide any financial guidance or operational outlook for the next quarter or upcoming year. No revenue or earnings forecast was offered by management in the latest earnings release. The company's leadership made clear that the near-term objective is to complete the planned merger and monetize or transfer its remaining assets. Because Pulmatrix is not currently developing or selling any medications, its short-term future is heavily dependent on successful asset divestitures and getting the Cullgen deal across the finish line. Investors and observers should monitor progress toward merger closing, potential updates on the sale of iSPERSE™-related patent portfolios, and any royalty developments with former pipeline candidates. PULM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
5 hours ago
- CTV News
Union sounding alarm on home-care changes
Union sounding alarm on home-care changes New changes for home care scheduling are creating challenges for nurses and families. CTV's Danton Unger reports.
CBC
5 hours ago
- CBC
RFK Jr.'s move to axe $500M in vaccine funding slammed
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has announced a $500-million cut to funding for mRNA vaccine development, insisting the technology used in COVID-19 vaccines poses risks. Many medical experts say the reasoning is untrue and could slow development of future vaccinations.
